BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Shanghai Unicar-Therapy Bio-medicine Technology Co.\,Ltd reado
 uts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Shanghai Unicar-Therapy Bio-medic
 ine Technology Co.\,Ltd's drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07036250-2970@assetmemo.bio
DTSTAMP:20261121T010844Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:U32 CAR-T: Phase 1/2 readout est. (NCT07036250)
DESCRIPTION:U32 CAR-T\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: Clinica
 l Study of U32 in Patients With Acute Myeloid Leukemia\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/u32-car-t#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07036250
URL:https://assetmemo.bio/drug/u32-car-t#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
